Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers [Phase 2]
Phase II randomized trial assessing immunotherapy plus radiotherapy in metastatic genitourinary cancers; study terminated with results poste…
-
CLINICAL_TRIALS trial_result · 2021-09-20Clinical Trial Update: A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma [Phase 2]
Phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma has completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-09-20Clinical Trial Update: Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) [Phase 2]
Phase 2 trial comparing pazopanib to temsirolimus in poor-risk clear-cell renal cell carcinoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-09-17Clinical Trial Update: Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases [Phase 2]
A Phase 2 trial evaluating sorafenib efficacy in renal cell carcinoma patients after radical resection of metastases is in development, with…
-
CLINICAL_TRIALS trial_result · 2021-09-13Clinical Trial Update: Robotic-assisted vs. Open Partial Nephrectomy [Phase 2]
Phase 2 clinical trial comparing robotic-assisted to open partial nephrectomy for renal cell carcinoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-09-01Clinical Trial Update: A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients [Phase 2]
Phase 2 trial evaluating pembrolizumab with SBRT in patients with stage IV renal cell cancer (AJCC 7th edition) has completed.
-
FDA approval · 2021-08-30FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
The FDA approved a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals, enabling an updated indication …
-
FDA approval · 2021-08-16FDA Approved: SUNITINIB MALATE — Original Application (NorthStar RxLLC)
FDA approved the original application for sunitinib malate, authorizing a generic version of the cancer drug from NorthStar RxLLC.
-
CLINICAL_TRIALS trial_result · 2021-08-06Clinical Trial Update: Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab plus axitinib as neoadjuvant therapy for locally advanced non-metastatic clear cell renal ce…
-
CLINICAL_TRIALS trial_result · 2021-07-12Clinical Trial Update: A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer [Phase 2]
Phase 2 trial evaluating sintilimab in combination with axitinib for advanced renal cell carcinoma, including clear cell histology.
-
CLINICAL_TRIALS trial_result · 2021-06-30Clinical Trial Update: Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion [Phase 2]
Phase 2 trial evaluating axitinib for reducing extent of venous tumor thrombus in renal cell carcinoma with venous invasion has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma [Phase 1]
Phase 1 study assessing safety and functional imaging of cG250 with sunitinib in advanced renal cell carcinoma was terminated; results poste…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma [Phase 4]
Phase 4 clinical trial update for Aldesleukin in participants with metastatic renal cell carcinoma or metastatic melanoma has completed with…
-
CLINICAL_TRIALS trial_result · 2021-06-03Clinical Trial Update: Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence [Phase 2]
Phase 2 trial of Vitespen (HSPPC-96, Oncophage) for immune response in resectable renal cell carcinoma at intermediate risk of recurrence; s…
-
CLINICAL_TRIALS trial_result · 2021-05-28Clinical Trial Update: A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. [Phase 2]
A Phase 2 rollover study of tremelimumab for patients who had received it in other protocols, to provide continued access until it becomes c…
-
CLINICAL_TRIALS trial_result · 2021-05-24Clinical Trial Update: Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial of dalantercept in combination with axitinib for advanced renal cell carcinoma was terminated; results posted in 2021…
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
Retrospective study update on referral patterns for high-risk patients after nephrectomy in renal cell carcinoma; results have been posted.
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. [Phase 1]
Phase 1 safety study assessing cG250 antibody labeled with 124-Iodine for diagnosing renal masses has been completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-05-10Clinical Trial Update: A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer [Phase 2]
A Phase II trial of the DNA methyltransferase inhibitor guadecitabine (SGI-110) in children and adults with wild-type GIST, paraganglioma, p…
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer [Phase 2]
Phase 2 trial evaluating a biomarker-driven strategy with nivolumab plus ipilimumab or VEGFR TKI in first-line clear cell metastatic renal c…
-
CLINICAL_TRIALS trial_result · 2021-04-26Clinical Trial Update: A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma [Phase 2]
Phase 2 trial update for CaBozantinib in metastatic/metastatic renal cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating sorafenib with gemcitabine and capecitabine in unresectable or metastatic renal cell carcinoma; results posted af…
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer [Phase 1, Phase 2]
Phase 1/2 study of sacituzumab govitecan-hziy (IMMU-132) in adults with epithelial cancers; trial completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-04-02Clinical Trial Update: Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
A completed clinical trial assessing outcomes for metastatic renal cell carcinoma patients who received sunitinib after first-line immune-on…
-
CLINICAL_TRIALS trial_result · 2021-03-30Clinical Trial Update: SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients [Phase 2]
Phase 2 trial evaluating SBRT with nivolumab/ipilimumab in metastatic/Stage IV kidney cancer has completed with results posted in 2021.